IDOV-SAFE
Phase 2Biologic
IDOV-SAFE is one of 20 biologic programs targeting Intravenous Administration. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Rare Tumor
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Gleevec
NovartisPhase 2
Alecensa
RochePhase 2
Vizimpro
PfizerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ibrance
PfizerPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Xalkori
PPrism Pharmaceuticals
Phase 2
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intravenous Administration1 trial
Rare Tumor1 trial
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IDOV-SAFE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University